Evaluation of 12-Lipoxygenase (12-LOX) and Plasminogen Activator Inhibitor 1 (PAI-1) as Prognostic Markers in Prostate Cancer
Figure 1
Expression of 12-LOX in platelet-rich plasma of BPH and prostate cancer patients. Normalization to PLT and TBG greatly increases sensitivity of correlation. Box and whisker plots of expression of 12-LOX () (a), 12-LOX normalized to PLT () (b), and 12-LOX normalized to TBG (5) (c) for BPH and prostate cancer. Solid, horizontal line inside box represents the median, position of the little square gives the average, box encompasses results within 25–75%, and wiskers mark values between 5–95%.